Volume 23 Issue 4
Apr.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(4): 573-575
ZHANG Wenhui, PEI Xiaohang, KONG Dai, ZHANG Ping, CHEN Xiangli, ZANG Yuzhu, LIU Zhongwen. Clinical observations of homoharringtonine with venetoclax and azacitidine in the treatment of FLT3-ITD mutation relapsed/refractory acute myeloid leukemia[J]. Chinese Journal of General Practice, 2025, 23(4): 573-575. doi: 10.16766/j.cnki.issn.1674-4152.003953
Citation: ZHANG Wenhui, PEI Xiaohang, KONG Dai, ZHANG Ping, CHEN Xiangli, ZANG Yuzhu, LIU Zhongwen. Clinical observations of homoharringtonine with venetoclax and azacitidine in the treatment of FLT3-ITD mutation relapsed/refractory acute myeloid leukemia[J]. Chinese Journal of General Practice, 2025, 23(4): 573-575. doi: 10.16766/j.cnki.issn.1674-4152.003953
shu

Clinical observations of homoharringtonine with venetoclax and azacitidine in the treatment of FLT3-ITD mutation relapsed/refractory acute myeloid leukemia

doi: 10.16766/j.cnki.issn.1674-4152.003953

  • Department of Hematology, Henan Provincial People' s Hospital, People' s Hospital of Zhengzhou University, Zhengzhou, Henan 450002, China

Funds:

 LHGJ20230016

 JQRC2023014

 SBGJ202102041

  • Received Date: 2024-07-22
    Available Online: 2025-06-30
    Abstract
  •   Objective  To explore the clinical effects of homoharringtonine with venetoclax and azacitidine in the treatment of FLT3-ITD mutation relapsed/refractory acute myeloid leukemia (R/R AML) and to evaluate the survival and prognosis of patients.  Methods  Thirty-nine FLT3-ITD mutation R/R AML patients treated from October 2018 to June 2024 in Henan Provincial People' s Hospital were reviewed. According to the different treatment modes, 20 cases of taking the non-intensive chemotherapy (venetoclax and azacitidine) were included in the control group; 19 cases of taking the intensive chemotherapy (homoharringtonine with venetoclax and azacitidine) were included in the observation group. The hepatic and renal function, short-term effects, treatment prognosis, and toxicity were compared.  Results  (1) In the observation group, complete remission (CR)/ CR with incomplete hematologic recover (CRi) was achieved in 9 out of 19 patients, accounting for 47.37% (9/19) of the total cases in this group; in the control group, CR/CRi was achieved in 4 out of 20 patients, accounting for 20.00% (4/20) of the total cases in this group. The difference between the two groups was not statistically significant (P>0.05). There were no significant between-group differences in the overall response rate [ORR, 73.68% (14/19) vs. 50.00% (10/20), P > 0.05]. (2) The relapse-free survival (RFS) between groups was not significantly different (P > 0.05); the overall survival (OS) in the observation group was longer than the control group, with a statistically significant difference (P < 0.001). (3) There were no significant between-group differences in the haematological toxicity reaction rates [68.42% (13/19) vs. 55.00% (11/20), P > 0.05].  Conclusion  Homoharringtonine with venetoclax and azacitidine can improve the short-term effects, treatment prognosis, and safety for FLT3-ITD mutation relapsed/refractory acute myeloid leukemia patients.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    宗李红, 吴小霞, 张剑, 等. 维奈克拉联合阿扎胞苷治疗难治复发性急性髓系白血病疗效及安全性分析[J]. 中华血液学杂志, 2021, 42(10): 861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012

    ZHONG L H, WU X X, ZHANG J, et al. Analysis of the efficacy and safety of combination therapy with Vinaclotide and Azacitidine in the treatment of refractory and recurrent acute myeloid leukemia[J]. Chinese Journal of Hematology, 2021, 42(10): 861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012
    [2]
    于文静, 贾晋松, 王婧, 等. 维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效: 单中心数据[J]. 中华血液学杂志, 2022, 43(2): 134-140.

    YU W J, JIA J S, WANG J, et al. The short-term efficacy of combination therapy of Vinaclat and Azacitidine in the treatment of acute myeloid leukemia: single center data[J]. Chinese Journal of Hematology, 2022, 43(2): 134-140.
    [3]
    李慧, 庄海峰. 急性髓系白血病伴FLT3-ITD突变研究进展[J]. 中国实用内科杂志, 2022, 42(4): 340-344.

    LI H, ZHUANG H F. Research progress on FLT3-ITD mutation in acute myeloid leukemia[J]. Chinese Journal of Practical Internal Medicine, 2022, 42(4): 340-344.
    [4]
    张文荟, 陈香丽, 陈玉清, 等. 高三尖杉酯碱联合阿扎胞苷与Venetoclax治疗难治/复发急性髓系白血病疗效观察[J]. 新乡医学院学报, 2021, 38(6): 580-584.

    ZHANG W H, CHEN X L, CHEN Y Q, et al. Observation of the therapeutic effect of high homosophocarpine combined with Azacitidine and Venetoclax in the treatment of refractory/recurrent acute myeloid leukemia[J]. Journal of Xinxiang Medical College, 2021, 38(6): 580-584.
    [5]
    中华医学会血液学分会白血病淋巴瘤学组. 中国复发难治性急性髓系白血病诊疗指南(2023年版)[J]. 中华血液学杂志, 2023, 44(9): 713-716.

    Leukemia And Lymphoma Group, Hematology Branch, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of relapsed and refractory acute myeloid leukemia (2023 edition)[J]. Chinese Journal of Hematology, 2023, 44(9): 713-716.
    [6]
    中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版)[J]. 中华血液学杂志, 2017, 38(3): 177-182.

    Leukemia And Lymphoma Group, Hematology Branch, Chinese Medical Association. Chinese diagnosis and treatment guidelines for adult acute myeloid leukemia (non acute promyelocytic leukemia) (2017 edition)[J]. Chinese Journal of Hematology, 2017, 38(3): 177-182.
    [7]
    中华医学会血液学分会白血病淋巴瘤学组. 复发难治性急性髓系白血病中国诊疗指南(2017年版)[J]. 中华血液学杂志, 2017, 38(3): 183-184.

    Leukemia And Lymphoma Group, Hematology Branch, Chinese Medical Association. Chinese diagnosis and treatment guidelines for relapsed and refractory acute myeloid leukemia (2017 edition)[J]. Chinese Journal of Hematology, 2017, 38(3): 183-184.
    [8]
    张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007: 19-25.

    ZHANG Z N, SHEN T. Diagnostic and therapeutic criteria for hematological diseases[M]. Third Edition. Beijing: Science Press, 2007: 19-25.
    [9]
    李舒心, 陈嘉媛, 惠岩, 等. 高三尖杉酯碱对CEBPA蛋白表达的作用及机制研究[J]. 中国实验血液学杂志, 2023, 31(5): 1257-1262.

    LI S X, CHEN J Y, HUI Y, et al. Study on the effect and mechanism of homosophocarpine on CEBPA protein expression[J]. Chinese Journal of Experimental Hematology, 2023, 31(5): 1257-1262.
    [10]
    FLEISCHMANN M, SCHOLL S, FRIETSCH J J, et al. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia[J]. J Cancer Res Clin, 2022, 148(11): 3191-3202. doi: 10.1007/s00432-022-03930-5
    [11]
    翁光样, 游伟文, 刘焕勋, 等. 维奈克拉联合阿扎胞苷治疗FLT3-ITDmut复发难治急性髓系白血病的疗效分析[J]. 中国实验血液学杂志, 2023, 31(5): 1333-1339.

    WENG G Y, YOU W W, LIU H X, et al. Analysis of the therapeutic effect of combination therapy of vinaclotide and azacitidine in the treatment of FLT3-ITDmut relapsed and refractory acute myeloid leukemia[J]. Chinese Journal of Experimental Hematology, 2023, 31(5): 1333-1339.
    [12]
    林先凤, 彭宏凌, 王志华, 等. AZA联合HHT和LDAC治疗3+7常规方案不耐受的急性髓系白血病患者的疗效和安全性[J]. 中国医师杂志, 2023, 25(8): 1159-1164. doi: 10.3760/cma.j.cn431274-20230110-00031

    LIN X F, PENG H L, WANG Z H, et al. The efficacy and safety of AZA combined with HHT and LDAC in the treatment of acute myeloid leukemia patients with 3+7 conventional regimen intolerance[J]. Chinese Journal of Physicians, 2023, 25(8): 1159-1164. doi: 10.3760/cma.j.cn431274-20230110-00031
    [13]
    李军, 黄炎青, 訾杰, 等. 阿扎胞苷联合高三尖杉酯碱通过调控c-MYC/DDIT3/PUMA轴协同抗急性髓系白血病的研究[J]. 中华血液学杂志, 2023, 44(12): 1001-1009. doi: 10.3760/cma.j.issn.0253-2727.2023.12.006

    LI J, HUANG Y Q, XU J, et al. A study on the synergistic anti acute myeloid leukemia effect of azacitidine combined with homoquercetin by regulating the c-MYC/DDIT3/PUMA axis[J]. Chinese Journal of Hematology, 2023, 44(12): 1001-1009. doi: 10.3760/cma.j.issn.0253-2727.2023.12.006
    [14]
    陈月梅, 金咏梅, 曾婷婷, 等. FLT3-ITD等多种基因突变原发性急性髓系白血病伴BCR-ABL1患者实验室检测结果分析[J]. 检验医学, 2022, 37(4): 365-369. doi: 10.3969/j.issn.1673-8640.2022.04.012

    CHEN Y M, JIN Y M, ZENG T T, et al. Analysis of laboratory test results for primary acute myeloid leukemia with BCR-ABL1 and multiple gene mutations such as FLT3-ITD[J]. Laboratory Medicine, 2022, 37(4): 365-369. doi: 10.3969/j.issn.1673-8640.2022.04.012
    [15]
    陈晓奉, 王蒙, 李忠玉, 等. Venetoclax联合化疗治疗复发/难治性急性髓系白血病的临床研究[J]. 中国全科医学, 2022, 25(8): 957-962.

    CHEN X F, WANG M, LI Z Y, et al. Clinical study on Venetoclax combined with chemotherapy for recurrent/refractory acute myeloid leukemia[J]. Chinese General Practice, 2022, 25(8): 957-962.
    [16]
    冯会欣, 杨艳丽, 耿英华. FLT3-ITD阳性急性髓系白血病免疫表型及临床特征研究[J]. 中华全科医学, 2021, 19(4): 572-576. doi: 10.16766/j.cnki.issn.1674-4152.001864

    FENG H X, YANG Y L, GENG Y H. Immunophenotypes and clinical characteristics of acute myeloid leukemia with positive FLT3-ITD[J]. Chinese Journal of General Practice, 2021, 19(4): 572-576. doi: 10.16766/j.cnki.issn.1674-4152.001864
    [17]
    MI R, ZHAO J, CHEN L, et al. Efficacy and safety of homoharringtonine for the treatment of acute myeloid leukemia: a meta-analysis[J]. Cl Lymph Myelom Leuk, 2021, 21(10): E752-E767. doi: 10.1016/j.clml.2021.06.002
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return